Medication Adherence for Aura

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Aura+2 More
Medication Adherence - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing different ways to help people with epilepsy manage their condition better. The hope is that this will lead to patients having fewer seizures.

Eligible Conditions
  • Aura
  • Epilepsy

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: To be administered at baseline (upon subject screening), pre-intervention (with 2 weeks prior to intervention), post-intervention (between 6 weeks to 3 months post-intervention), and delayed post-intervention (within 4&1/2 to 6 months post-intervention)

Month 6
Changes in Quality of Life in Epilepsy-10 scores

Trial Safety

Trial Design

1 Treatment Group

Epilepsy Patients
1 of 1
Experimental Treatment

568 Total Participants · 1 Treatment Group

Primary Treatment: Medication Adherence · No Placebo Group · N/A

Epilepsy PatientsExperimental Group · 4 Interventions: Memory Improvement, Stress Management, Medication Adherence, Seizure Documentation · Intervention Types: Behavioral, Behavioral, Behavioral, Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stress Management
2011
N/A
~2760

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: to be administered at baseline (upon subject screening), pre-intervention (with 2 weeks prior to intervention), post-intervention (between 6 weeks to 3 months post-intervention), and delayed post-intervention (within 4&1/2 to 6 months post-intervention)

Who is running the clinical trial?

Dupont Fund, Jesse BallUNKNOWN
Riverside Hospital FoundationUNKNOWN
Florida Blue FoundationUNKNOWN
University of FloridaLead Sponsor
1,236 Previous Clinical Trials
696,467 Total Patients Enrolled
Ramon Edmundo D Bautista, MDPrincipal InvestigatorUniversity of Florida

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a clinical diagnosis of epilepsy using established criteria.
You are able to provide informed consent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: October 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.